News and Trends 27 Apr 2016
French Pleodrug for Rare Neurological Disease opens up phase III trial in US
Pharnext is opening their first US study sites for a phase III trial in a rare neuropathy – a milestone in the development of Pharnext’s leading candidate. Based in Paris (France), Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. Pharnext uses network pharmacology to discover synergistic combinations of drugs […]